LITTLE FALLS, N.J., Jan. 20, 2011 /PRNewswire/ -- Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs, announced today that the company will be represented by former U.S. Congressman Curt Weldon at The Future of Financial Markets (FOFM 2011) Leadership Summit, January 20-22, 2011, at the Renaissance Mumbai Convention Centre Hotel, Powai, Mumbai. This Annual Conference is invitation only and attended by 400 of India's premier financial and investment leaders.
"This conference provides an opportunity for Curt to speak passionately about Regenicin and the company's role in bringing new breakthroughs in regenerative medicine to market," says Regenicin's CEO, Randall McCoy, who recently contracted the former Congressman as a business development consultant for the company. "It also provides the perfect forum for Curt to explore business development and investment opportunities for Regenicin in the global market."
Weldon, who served as a Republican member of the United States House of Representatives from 1987-2007, representing the 7th district of Pennsylvania, will present Regenicin's unique business model and core strategy for 2011. Key components of Regenicin's strategy include identifying promising new therapeutic candidates that address unmet needs in growing markets; developing the most strategic, economical and expeditious pathways for achieving regulatory approval by the FDA; and creating a commercialization pipeline for bringing new candidates to market once FDA approved.
Currently Regenicin is playing a critical role in developing an exciting breakthrough technology that uses the patient's own skin cells to generate living, tissue-engineered skin for the treatment of catastrophic burns.
Weldon, who founded the Congressional Fire Services Caucus in 1987, is passionate about supporting fire fighters who are critically injured in the line of duty. While in Congress he authored a bill that implemented a federal grant program for local fire departments. In addition, he fought for mandatory safety sprinklers in college dormitories and training of fire departments to deal with terrorism incidents involving chemical and biological weapons. While a member of Congress Weldon also served as the vice-chair of the Armed Services Committee and the House Homeland Security Committee.
Regenicin, Inc., (www.regenicin.com) is a biotechnology company specializing in the development of and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was founded in 2010, has assembled a world class team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market. Regenicin is playing a critical role in developing an exciting breakthrough technology that uses the patient's own skin cells to generate living, tissue-engineered skin for the treatment of chronic burns. The company is publicly traded with headquarters in New Jersey. Additional information can be found in the company's filings with the Securities and Exchange Commission located at www.sec.gov.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
|SOURCE Regenicin, Inc.|
Copyright©2010 PR Newswire.
All rights reserved